The two companies decided to conduct a Phase 2 clinical trial of the drug after confirming the safety of the drug in animals and humans, and submitted a notification of clinical trial (CTN) to the Pharmaceuticals and Medical Devices Agency (PMDA)
The ointment is developed based on KinoPharma’s novel HPV antivirals. (Credit: May Angelike from Pixabay)
Japanese pharmaceutical companies KinoPharma and IWAKI SEIYAKU have jointly launched a Phase 2 clinical trial to confirm the efficacy of a drug candidate in treating cutaneous warts.
Cutaneous warts are small proliferative non-cancerous lesions (benign tumours), caused by infection with the human papillomavirus (HPV) family.
The general treatment methods include cryotherapy using liquid nitrogen, which requires repeated procedures and is associated with pain related to the treatment.
Since January 2021, the two companies have been jointly developing an ointment based on KinoPharma’s novel concept of HPV antiviral drugs targeting human host factors.
In August last year, the collaboration was extended with a co-development and commercialisation agreement to advance the development for the indication of cutaneous warts.
The companies decided to conduct a Phase 2 clinical trial of the drug against cutaneous warts, after confirming its safety in animals and humans.
The two companies have now submitted a notification of clinical trial (CTN) to the Pharmaceuticals and Medical Devices Agency (PMDA).
HPV has been named based on the formation of a characteristic papilla-like tumour when with its infection on the skin or other parts of the body.
The family of the virus include more than 100 different types, and their infections are known to cause skin, anogenital, reproductive organ and upper aerodigestive tract diseases.